Overview

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Status:
Completed
Trial end date:
2018-10-11
Target enrollment:
Participant gender:
Summary
Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of multiple doses.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer